TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03952507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 600 (Oral Tablet Formulation)
Description: Participants will receive 600 mg of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 600 (Oral Tablet Formulation)
Description: Participants will receive 600 mg of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 600 (Oral Tablet Formulation)
Description: Participants will receive 600 mg of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 600 (Oral Tablet Formulation)
Description: Participants will receive 600 mg of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 600 (Oral Tablet Formulation)
Description: Participants will receive 600 mg of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 600 (Oral Tablet Formulation)
Description: Participants will receive 600 mg of JNJ-64417184 as oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 (Oral Suspension Formulation)
Description: Participants will also receive JNJ-64417184 600 mg as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 (Oral Suspension Formulation)
Description: Participants will also receive JNJ-64417184 600 mg as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 (Oral Suspension Formulation)
Description: Participants will also receive JNJ-64417184 600 mg as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 (Oral Suspension Formulation)
Description: Participants will also receive JNJ-64417184 600 mg as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 (Oral Suspension Formulation)
Description: Participants will also receive JNJ-64417184 600 mg as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184 (Oral Suspension Formulation)
Description: Participants will also receive JNJ-64417184 600 mg as oral suspension.
Study: NCT05258955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural honey
Description: Natural Sidr honey based mouthwash used as intervention group B (Arm Group B) for the reduction of plaque index

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine gluconate 0.12% mouthwash is used as intervention in Group A (Arm Group A) for the comparison of plaque reduction among group A and B
Study: NCT03984877

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of amyloidosis
Description: Scintigraphy and protein electrophoresis

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of amyloidosis
Description: Scintigraphy and protein electrophoresis
Study: NCT00478647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GA-GCB (velaglucerase alfa)
Description: 15-60 U/kg, every other week via intravenous infusion
Study: NCT03740204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-β estradiol transdermal patches with cyclic progesterone
Description: 17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch and pill
Description: Placebo patch and pill
Study: NCT00197106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg
Description: comparator

Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone propionate 2 x 100 mcg
Description: comparator
Study: NCT01452737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bowel Prep
Description: Subjects will be asked to take 4L of Golytely the day prior to procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L Golytely/bisacodyl
Description: Subjects will be asked to take 2L Golytely and 15mg bisacodyl the day prior to procedure.
Study: NCT03691545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive sessions
Description: This arm will receive personalized health coaching (behaviour change counseling)
Study: NCT03062449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Serine
Description: Gummy containing L serine dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gummy
Description: Gummy with no dosing of L Serine
Study: NCT01830062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS
Description: Near infrared spectroscopy of at least 2 major epicardial vessels

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CACS
Description: Coronary artery calcium score assessed by multi-slice computed tomography
Study: NCT00636662

Intervention type: OTHER
Intervention: Non-invasive diagnostic testing
Description: No patient treatment is altered by enrollment in this trial
Study: NCT01565317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Achievement and Intensive Treatment (Why WAIT)
Description: Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
Study: NCT03051425

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Description: 120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 120 mL of low-fat milk
Study: NCT02466243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE.
Study: NCT01921907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD17137 topical treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04329546

Intervention type: OTHER
Intervention: NA (no intervention)
Description: NA (no intervention)

Intervention type: OTHER
Intervention: NA (no intervention)
Description: NA (no intervention)
Study: NCT03498586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half-normal saline
Description: Use of half-normal saline as an irrigant for open-irrigated ablation catheters

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Use of normal saline as an irrigant for open-irrigated ablation catheters
Study: NCT00639769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Starting dose 30 mg/m2 Dose level -1 20 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.
Study: NCT04008147

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 100mg iron fumarate
Description: 100mg iron fumarate b.i.d. for 4 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Burgerstein Schwangerschaft & Stillzeit
Description: contains 30 mg iron fumarate, given on 14 consecutive days
Study: NCT05815823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic exercise therapy
Description: Functional exercise programs such as collecting rain in a glass, grating vegetables, goalkeeper, cleaning the stove, watering flowers, wiping windows, catching fish, and exploring landscapes were applied by robotic games to the patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: streching, range of motion, strengthening, balance and walking exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: streching, range of motion, strengthening, balance and walking exercise
Study: NCT02985047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Admission
Description: Participants randomised to Brief admission (BA) will participate in a negotiation together with their out-patient clinician and a representative from the ward. The aim of the negotiation is to form an individualised contract defining how BA will work for them. After signing the contract, will have the possibility to admit themselves to hospital according to the procedure stated in the contract.
Study: NCT01674920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choices
Description: The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
Study: NCT01979263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification Computer Task
Description: Computer task aimed at actively modifying attention bias

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Computer Task
Description: Computer task that does not actively modify attention bias
Study: NCT01939951

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Activation Energy Serum
Description: 7 drops or 21 drops twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Activation Energy Serum
Description: 7 drops or 21 drops twice daily
Study: NCT01592812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical muscle stimulation
Description: Duration of the stimulation 20 minutes
Study: NCT04486313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets administered orally twice daily with food for 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind
Study: NCT02609152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous perfusion of esmolol
Description: In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continuous perfusion of saline
Description: In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
Study: NCT01159483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT01907113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: oral administration
Study: NCT02932085

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurostar TMS Therapy System, NeuroStar XPLOR System
Description: Repetitive transcranial magnetic stimulation
Study: NCT01583205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training - ALS
Description: Eight coping effectiveness training counseling sessions.
Study: NCT02932085

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostar TMS Therapy System, NeuroStar XPLOR System
Description: Repetitive transcranial magnetic stimulation
Study: NCT03182998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Knowing your Options decision aid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Prostate Choice decision aid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03737630

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training
Study: NCT00467402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00661544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Dose Levels 1, 2, \& 3: 100 mg/m2 IV Days -4, -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.
Study: NCT03371277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical visit for specific questionnaires
Description: Ambiguous Intentions Hostility Questionnaire (AIHQ) developed by Combs (2007)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical visit for specific questionnaires
Description: Ambiguous Intentions Hostility Questionnaire (AIHQ) developed by Combs (2007)
Study: NCT03613636

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunospot (ELISpot) assay [Blood]
Description: The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\].

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunospot (ELISpot) assay [Blood]
Description: The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\].

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunospot (ELISpot) assay [Blood]
Description: The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\].
Study: NCT02580175

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blinded evacuation
Description: Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evacuation under ultrasound guidance
Description: Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
Study: NCT04410809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-46
Description: Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same composition as the active medication but without the active substance TA-46
Study: NCT02345915

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram
Study: NCT02717442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Description: Single intratympanic injection of 12 mg OTO-104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study: NCT00542100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCMRI
Study: NCT01383447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT01383447

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study: NCT01752764

Intervention type: OTHER
Group type: OTHER
Intervention: Test product: Salad with a high dosage fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product: Salad with a high dosage fat
Study: NCT01026337

Intervention type: GENETIC
Intervention: mutation analysis
Description: Correlative study

Intervention type: OTHER
Intervention: pharmacological study
Description: Correlative study
Study: NCT01752764

Intervention type: OTHER
Group type: OTHER
Intervention: Control product: Salad with low dosage fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control product: Salad with low dosage fat
Study: NCT02561208

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Intervention Group
Description: Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.